Drug Profile


Alternative Names: Celecoxib/amlodipine; KIT 302

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Kitov Pharmaceuticals
  • Class Antihypertensives; Antirheumatics; Dihydropyridines; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Calcium channel antagonists; Cyclo-oxygenase 2 inhibitors; Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypertension; Pain

Most Recent Events

  • 07 Feb 2017 Israeli Securities Authority initiates formal investigation for amlodipine/celecoxib disclosures by Kitov Pharmaceuticals
  • 17 Jan 2017 Kitov Pharmaceuticals announces intention to submit NDA to the US FDA by March 2017
  • 07 Dec 2016 Amlodipine/celecoxib (KIT-302) successfully completes 6 months stability testing required for the submission of a NDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top